Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

The New England journal of medicine - 22 Oct 2020

Foà Robin, Bassan Renato, Vitale Antonella, Elia Loredana, Piciocchi Alfonso, Puzzolo Maria-Cristina, Canichella Martina, Viero Piera, Ferrara Felicetto, Lunghi Monia, Fabbiano Francesco, Bonifacio Massimiliano, Fracchiolla Nicola, Di Bartolomeo Paolo, Mancino Alessandra, De Propris Maria-Stefania, Vignetti Marco, Guarini Anna, Rambaldi Alessandro, Chiaretti Sabina

Abstract excerpt

BACKGROUND: Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment. METHODS: We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Hematopoietic Stem Cell Transplantation

Share to Induction Chemotherapy

Share to Philadelphia Chromosome

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Remission Induction

Source

Identifiers

PMID: 33085860
DOI: 10.1056/NEJMoa2016272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.PMID 33085860Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.Semantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Ph+ ALL: new approaches for upfront therapySemantic proximity Read ↗

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLSemantic proximity Read ↗

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adultsSemantic proximity Read ↗

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.Semantic proximity Read ↗

Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.